

CLAIMS

1. A pharmaceutical composition in the form of a unit dosage comprising 1 to 60 mg (+)-*erythro*-mefloquine, substantially free of the opposite enantiomer.
2. A composition according to claim 1, wherein the unit dosage is a tablet comprising a carrier and/or excipient.
3. A composition according to claim 1 or claim 2, wherein the unit dosage comprises up to 40 mg (+)-*erythro*-mefloquine.
4. A composition according to claim 3, wherein the unit dosage comprises up to 20 mg (+)-*erythro*-mefloquine.
5. A composition according to claim 3, wherein the unit dosage comprises up to 15 mg (+)-*erythro*-mefloquine.
6. A composition according to any preceding claim, wherein the unit dosage comprises at least 5 mg (+)-*erythro*-mefloquine.
7. Use of (+)-*erythro*-mefloquine for the manufacture of a composition according to any preceding claim, for use in the treatment of an inflammatory condition..
8. Use according to claim 7, wherein the condition is osteoarthritis.
9. Use according to claim 7, wherein the condition is rheumatoid arthritis.
10. Use according to any of claims 7 to 9, wherein the condition is also treated with an anti-TNF antibody.
11. Use according to any of claims 7 to 10, wherein the subject of treatment is also receiving an immunosuppressant.
12. Use according to claim 11, wherein the immunosuppressant is methotrexate.
13. A product comprising (+)-*erythro*-mefloquine and an anti-TNF antibody, as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition.
14. A product comprising (+)-*erythro*-mefloquine and an immunosuppressant as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition and where immunosuppression is also required.
15. A product according to claim 14, wherein the immunosuppressant is methotrexate.